Transdermal Corp is a development stage specialty drug delivery system technology company based in Birmingham, Michigan. The Company was formed in August 2008, in the State of Nevada, and has two subsidiaries: Transdermal IP Corp, a wholly-owned subsidiary and DPM Therapeutics Inc., an eighty-six percent (86%) owned subsidiary.
Trandermal Copr has developed patented technology consisting of a proprietary, non-invasive drug delivery system called, Ionic Nano Particle Technology (“INParT™”). Our technology has numerous applications including medical, aesthetic and skin care. The INParT Drug Delivery System provides a novel, unique, commercially viable trans-dermal and non-invasive drug delivery technology that enables delivery and absorption of active compounds though the stratum corneum and throughout the skin and sub cutaneous tissue without any cutaneous toxicity. Our primary focus will be to expand our patent portfolio, conduct additional clinical trials on our technology and seek to establish collaborative relationships with potential partners, including large pharmaceutical companies.
We intend to initially focus on the following four aesthetic and dermatological areas:
- Skin Care/Anti-Wrinkle Cream – Topical Hyaluronic Acid Organic Collagen (Dermal FxTM)
- Topical Toxin Cream for Wrinkle Removal and Hyperhidrosis – (containing Botulinum Neurotoxin Type -A (“BoNTA”)
- Acne – Benzoyl Peroxide; (low concentration, non-burning and non-scaling product)
Diseases such as acne, psoriasis, rosacea and melasma as well as cutaneous aesthetic enhancement could dramatically benefit from our ability to better transport active compounds to target tissue.
The Dermal FxTM product containing hyaluronic acid and collagen is being sold in the market today as an over the counter cosmeceutical. Our acne cream is approved for sale in Canada and received FDA approval in July 2010 and will be marketed and sold in the United States by the year end.
The company is working to develop a comprehensive line of skin care products using our InParT Drug Delivery System – Ionic Nano Particle Technology, which provides a novel, commercially viable trans-dermal and non-invasive drug delivery technology that enables delivery and absorption of active compounds through the stratum corneum and throughout the skin and sub cutaneous tissue without any cutaneous toxicity. Our business model is based upon achieving optimum value for our patented INParT Drug Delivery System and related patented technology and applications. We will seek to accomplish this through one or more of several ways, including, licensing arrangements, joint ventures, collaboration or sale.
Approximately $1.5-2.0 billion market opportunity.
Transdermal Corp’s Mission, Values & Purpose
Cutanea seeks to strategically in-license novel product candidates to treat diseased and aging skin and aggressively advance their development, maximize intellectual property and therapeutic applications to create market leading products for out-license or commercialization.
Integrity: Adhering to our words and representations.
Respect: To treat everyone fairly: investors, co-workers, advisors, vendors, and customers.
Discipline: To focus our time, energy and resources efficiently to drive value creation, excellence and work-life quality.
Resilience: To confront challenges and setbacks as opportunities to learn, improve and grow professionally, personally and economically.
Enterprising: To seize opportunities with creativity, energy, initiative, and ambition.
Networking: To proactively expand our circle of quality relationships in all facets of our business to complement and enhance our competencies.
Enhancing Health and Appearance